Telix Pharmaceuticals Upgraded to Moderate Buy Amid Analyst Consensus

Telix Pharmaceuticals (NASDAQ:TLX) has received an upgrade from Royal Bank Of Canada, which now rates the company as 'Moderate Buy'.

This move follows other recent upgrades and positive ratings from various analysts. Weiss Ratings upgraded Telix's shares from a 'Sell (d)' to a 'Hold (c-)', while Wedbush reiterated its 'Outperform' rating with a $22 price target. Citigroup also reaffirmed its 'Buy' rating, and HC Wainwright restated its 'Buy' rating with a $20 price objective.

As of Monday, shares of TLX stock opened at $11.31, down 10.2% from previous levels. The company's average price target is now $20.40, based on analyst consensus.